Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F16IL2 plus paclitaxel versus paclitaxel alone in metastatic Merkel cell carcinoma
2012-004018-33Phase 2Terminated
- Sponsor
- Philogen
- Start
- Nov 2012
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of teleukin and paclitaxel in Merkel cell carcinoma (MCC) (2 arms), sponsored by Philogen. Primary endpoint: Overall survival rate at 12 months. Started Nov 2012; status: terminated.
02
Drugs
teleukinpaclitaxel
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2012-004018-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004018-33.